BXTAccelyon sold to its management for an overall 6x return since original investment
BXTAccelyon
BXTAccelyon sold to its management for an overall 6x return since original investment
30.06.26
On 2nd August ,2013, the Fund completed the establishment of BXTA as a new company formed with experienced industry executives, Malcolm Hughes and Saheed Rashid, investing £2.45 million for 62.5% of the share capital. BXTA is a leading specialist uro-oncology diagnostics and therapy business supplying brachytherapy seeds to treat prostate cancer and the market leading transperineal biopsy device for the detection of prostate cancer. The business has market leading operations in the UK, Ireland, Australia, New Zealand and increasingly across mainland Europe.
£7.5 million was previously returned to investors (£4.5 million in December 2022 and £2.9 million in July 2023), which represented a 3.1x cash return on the total investment. On 30th June 2026, the Elysian funds received a further £7.0 million, which represents 2.9x the cost of investment, bringing the total return to 6.0x from the sale of the remaining Fund’s interests in the company to the existing management.
The sale of BXTA completes the last realisation in Elysian Capital I LP at an overall gross return of 2.8x.
Ken Terry, Chairman of Elysian Capital said, “BXTA has been a very successful investment for Elysian and together with management, we have built the leading business in brachytherapy for treating prostate cancer and for undertaking prostate biopsies. It is now time for management to continue and take the business to the next level and we wish Malcolm and Saheed all success in this next phase. It has been a pleasure working with them”.
Malcolm Hughes, Executive Chairman of BXTA said, “From investing in BXTA as a start-up through to their exit, Elysian has been a strong supporter of myself, Saheed and the global team we have built, helping us to establish the company as a leading international prostate cancer business. BXTA is now well positioned for the next stage of our journey as we aim to expand our uro-oncology capabilities into new products and new geographic territories”.